Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives - Cancer Treatment Reviews
IDO Is Still A Valid Pathway For NewLink Genetics (NASDAQ:LUMO) | Seeking Alpha
Proposed mechanism for formation of ¹O2 by IDO1 plus H2O2 and chemical... | Download Scientific Diagram
Epacadostat - Wikipedia
Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition - Kassab - 2021 - ChemMedChem - Wiley Online Library
Epacadostat - an overview | ScienceDirect Topics
The therapeutic potential of targeting tryptophan catabolism in cancer | British Journal of Cancer
Frontiers | Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations | Molecular Biosciences
Indoximod - an overview | ScienceDirect Topics
AACR-NCI-EORTC B060 IDO1 Inhibitors - Oncolines B.V.
Characterization of Apo‐Form Selective Inhibition of Indoleamine 2,3‐Dioxygenase** - Ortiz‐Meoz - 2021 - ChemBioChem - Wiley Online Library
aacrindoximod
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study | Journal for ImmunoTherapy of Cancer
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters
Overview of TRP-related IDO-inhibitors currently under investigation... | Download Scientific Diagram
Biomedicines | Free Full-Text | Cancer Vaccines in Ovarian Cancer: How Can We Improve? | HTML
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1 | Aging
Epacadostat - Launch Insight, 2019 - Research and Markets
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. - Abstract - Europe PMC
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy | Journal of Hematology & Oncology | Full Text
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer -
INCB24360 (epacadostat) – All About Drugs
Frontiers | Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers | Oncology
